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Summary
Background.  —  Transcatheter  valve-in-valve  (VIV)  implantation  in  failing  bioprosthesis  is  an
emerging ﬁeld  in  cardiology.
Aim.  —  To  report  on  a  French  multicentre  experience  and  a  literature  review  of  tricuspid  VIV
implantation.
Methods. —  We  approached  different  institutions  and  collected  10  unpublished  cases;  a  litera-
ture review  identiﬁed  71  patients,  including  our  10  cases.  Clinical  aspects  and  haemodynamic
data are  discussed.
Results.  —  Among  our  10  unpublished  cases,  the  reason  for  implantation  was  signiﬁcant  tricuspid
stenosis (n  =  4),  signiﬁcant  tricuspid  regurgitation  (n  =  1)  or  mixed  lesion  (n  =  5).  Implantation  was
performed  under  general  anaesthesia  at  mean  age  28  ±  17  years.  The  22  mm  Melody  valve  was
Abbreviations: NYHA, New York Heart Association; VIV, valve-in-valve; VIR, valve-in-ring.
∗ Corresponding author.
E-mail addresses: francois.godart@chru-lille.fr, cfda.godart@orange.fr (F. Godart).
http://dx.doi.org/10.1016/j.acvd.2014.07.051
1875-2136/© 2014 Elsevier Masson SAS. All rights reserved.
584  F.  Godart  et  al.
implanted  in  seven  patients;  the  Edwards  SAPIEN  valve  was  implanted  in  three  patients.  The
procedure succeeded  in  all  cases,  despite  two  embolizations  in  the  right  cardiac  chambers;  in
both cases,  the  valve  was  stabilized  close  to  the  tricuspid  annulus  using  a  self-expandable  stent,
before implantation  of  a  second  Edwards  SAPIEN  valve.  Functional  class  improved  in  all  but  one
case. Mean  diastolic  gradient  decreased  from  9  ±  2.45  mmHg  to  3.65  ±  0.7  mmHg  (p  =  0.007);
no more  than  trivial  regurgitation  was  noticed.  Among  the  published  cases,  the  Melody  valve
was implanted  in  41  patients,  the  Edwards  SAPIEN  valve  in  29  patients  and  the  Braile  valve  in
one patient.  Short-term  results  were  similar  for  our  10  cases,  but  mid-term  results  are  not  yet
available.
Conclusions.  —  Tricuspid  VIV  implantation  using  the  Melody  or  Edwards  SAPIEN  valves  is  a  fea-
sible and  effective  procedure  for  selected  patients  with  failing  bioprosthesis.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
MOTS  CLÉS
Remplacement
valvulaire  VIV  ;
Tricuspide  ;
Valve  Melody  ;
Valve  SAPIEN
d’Edwards
Résumé
Contexte.  —  Le  remplacement  valvulaire  percutanée  avec  la  technique  « valve-in-valve  » (VIV)
dans une  bioprothèse  défaillante  est  une  technique  innovante  en  cardiologie.
Objectif.  —  Le  but  de  cette  étude  est  de  rapporter  une  expérience  franc¸aise  dans  le  remplace-
ment tricuspide  VIV  et  une  revue  de  la  littérature.
Méthodes.  —  Nous  avons  approché  différents  centres  et  collecté  10  cas  non  publiés.  Une  revue
de la  littérature  a  pu  identiﬁer  71  patients  incluant  nos  10  patients.
Resultats.  —  Cas  non  publiés  :  les  raisons  du  remplacement  étaient  une  sténose  tricuspide  signi-
ﬁcative (n  =  4),  une  fuite  tricuspide  signiﬁcative  (n  =  1)  et  une  lésion  mixte  (n  =  5).  La  mise  en
place a  été  effectuée  à  un  âge  moyen  de  28  ±  17  ans.  Une  valve  Melody  de  22  mm  a  été  implan-
tée chez  7  patients,  une  valve  SAPIEN  d’Edwards  chez  3  patients.  L’implantation  a  réussi  chez
tous les  patients  malgré  2  embolisations  dans  les  cavités  droites  :  la  valve  a  été  stabilisée
contre  l’anneau  tricuspide  avec  un  stent  auto-expansif  avant  l’implantation  d’une  seconde
valve SAPIEN  d’Edwards.  Chez  tous  les  patients  sauf  un,  la  classe  fonctionnelle  s’est  améliorée.
Le gradient  tricuspide  est  passé  de  9  ±  2,45  mmHg  à  3,65  ±  0,7  mmHg  (p  =  0,007),  et  les  patients
n’avaient  plus  de  fuite  tricuspide  ou  une  minuscule.  La  revue  de  la  littérature  :  une  valve  Melody
a été  implantée  chez  41  patients,  une  valve  Edwards  SAPIEN  chez  29  patients,  et  une  valve  Braile
chez un  patient.  Les  résultats  immédiats  sont  comparables  à  ceux  de  cette  série  mais  les  résul-
tats à  moyen  terme  ne  sont  pas  encore  disponibles.  Les  aspects  cliniques  et  hémodynamiques
sont discutés.
Conclusion.  — Le  remplacement  tricuspide  par  une  technique  VIV  utilisant  la  valve  Melody  ou
la valve  SAPIEN  d’Edwards  est  réalisable  et  efﬁcace  chez  des  patients  sélectionnés  avec  une
bioprothèse  défaillante.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ricuspid  valve  disease  is  not  rare,  and  can  be  observed  in
bstein’s  anomaly  and  after  ventricular  septal  defect  closure
r  Fallot  repair,  rheumatic  valve  disease  or  endocarditis;
t  can  also  be  caused  by  annulus  dilatation  secondary  to
ulmonary  hypertension.  Patients  with  this  disease  often
equire  tricuspid  valve  replacement  with  a  bioprosthe-
is,  and  need  reinterventions  over  time  because  of  valve
egeneration  [1—3].  However,  reoperative  valve  replace-
ent  carries  a  higher  risk  of  mortality  and  morbidity  for
hese  patients,  who  are  usually  in  poor  clinical  condition
ompared  with  when  they  had  the  initial  valve  replacement
1—3].  The  procedure  may  be  also  very  challenging  in  terms
f  the  technical  aspects  of  the  correction  itself,  with  a  risk  of
xtensive  damage  to  the  myocardium  and  the  atrioventric-
lar  junction.  Transcatheter  VIV  implantation  has  recently
merged  as  a  therapeutic  approach  for  failing  bioprosthetic
t
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salves.  The  presence  of  prosthetic  material  provides  a  sup-
ort  for  the  valved  stent.  There  are  a  few  publications  on
he  use  of  both  the  Edwards  SAPIENTM valve  (Edwards  Life-
ciences,  Irvine,  CA,  USA)  and  the  Melody® valve  (Medtronic
nc.,  Minneapolis,  MN,  USA),  but  most  are  case  reports.  This
tudy  describes  a  French  multicentre  experience  (unpub-
ished)  and  a  literature  review  of  tricuspid  VIV  implantation;
echnical  aspects  are  discussed.
ethods
 data  sheet  was  circulated  to  different  centres  involved
n  percutaneous  pulmonary  valve  implantation  and  known
o  have  performed  transcatheter  tricuspid  VIV  implanta-
ion.  For  each  patient,  the  following  data  were  collected:
ge;  weight;  sex;  initial  diagnosis;  number  of  previous
urgical  interventions;  number  of  previous  tricuspid  valve
t
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procedures;  preprocedure  clinical  condition;  indication  for
tricuspid  valve  repair;  characteristics  of  the  implanted  tri-
cuspid  prosthesis;  pre-  and  postechocardiographic  data;
complications;  and  follow-up.  We  report  here  on  10  cases
from  four  centres.  Most  of  the  investigators  belong  to  the
‘Groupe  de  cathétérisme  interventionnel  pédiatrique  et
congénitale,  ﬁliale  de  cardiologie  pédiatrique  et  congénitale
de  la  Société  franc¸aise de  cardiologie’.
In  addition,  we  searched  the  online  medical  database
‘PubMed’  for  all  publications  on  ‘tricuspid  VIV  implanta-
tion’  using  both  the  Melody  and  the  Edwards  SAPIEN  valves.
We  reviewed  patient  data,  procedural  details,  valve  perfor-
mance  and  outcome.
Continuous  data  are  presented  as  means  ±  standard  devi-
ations  (range).  Paired  t  tests  and  Wilcoxon  tests  were  used  to
compare  pre-  and  post-procedure  gradients  within  patients.
Results
French multicentre experience of tricuspid
VIV implantation
Patient  population
Table  1  outlines  the  baseline  characteristics  of  the  10  study
patients;  most  of  the  patients  had  congenital  heart  dis-
ease.  Mean  age  at  implantation  was  28  ±  17  years  (range
9—60  years);  ﬁve  patients  were  aged  ≤  18  years  at  implanta-
tion.  The  mean  time  period  between  tricuspid  bioprosthesis
implantation  and  dysfunction  requiring  VIV  implantation  was
12  ±  9.7  years  (range  3—32  years).  The  size  of  the  dysfunc-
tional  valve  ranged  from  23  to  33  mm  (mean  29.5  ±  3.6  mm).
All  patients  presented  signs  of  right  heart  failure.  Five
patients  were  in  New  York  Heart  Association  (NYHA)  func-
tional  class  III,  three  were  in  class  II  and  two  were  in
class  IV.  In  addition,  two  patients  presented  with  protein-
losing  enteropathy.  After  a  multidisciplinary  discussion,  the
patients  were  referred  for  percutaneous  VIV  implantation.
At  baseline,  the  tricuspid  maximal  gradient  was
16  ±  2.5  mmHg  and  the  mean  gradient  was  9  ±  2.4  mmHg.
Reason  for  VIV  implantation  was  a  predominant  tricus-
pid  stenosis  (deﬁned  as  mean  gradient  >  5  mmHg)  (n  =  4),
a  signiﬁcant  tricuspid  regurgitation  (moderate-to-severe
p
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Table  1  Patient  data:  unpublished  cases  of  tricuspid  valve-in
Patient  Age  (years)  Sex  Weight  (kg)  Pathology  
1  16  M  45  Ebstein’s  anomaly  
2  15  M  59  Ebstein’s  anomaly  
3  60  F  61  Ebstein’s  anomaly
4  14  F  54  Ventricular  septal  d
5  26  F  68  Tricuspid  dysplasia  
6  9  M  22  Arterial  duct,  pulm
7  33  F  59  Cardiomyopathy  
8  44  M  85  Tricuspid  atresia,  F
9  49  M  57  Rheumatic  
10  17  M  55  Ebstein’s  anomaly  
CE: Carpentier-Edwards; F: female; M: male.585
ricuspid  regurgitation)  (n  =  1)  or  a  mixed  lesion  combining
igniﬁcant  tricuspid  stenosis  and  regurgitation  (n  =  5).
rocedures
nformed  consent  was  obtained  from  all  patients.  The  pro-
edure  was  done  under  general  anaesthesia.  Owing  to
otential  complications  requiring  emergency  surgery,  sur-
ical  backup  was  available  for  most  of  the  implantations.
alloon  sizing,  using  a  low-pressure  balloon  catheter  to
elineate  the  dimension  of  the  annulus,  was  employed
n  nine  patients;  predilatation  using  a  high-pressure  bal-
oon  was  performed  in  ﬁve  patients.  Before  implantation,
restenting  was  done  in  six  patients,  including  one  who  had
our  stents  implanted  to  reduce  the  annulus  size  before
mplantation  of  a  22-mm  Melody  valve.  All  patients  under-
ent  successful  VIV  implantation:  the  Melody  valve  was  used
n  seven  patients;  the  Edwards  SAPIEN  valve  was  used  in
hree  patients.
No  periprocedural  death,  myocardial  infarction,  stroke  or
tent  fracture  occurred.  Two  embolizations  of  the  Edwards
APIEN  valve  within  the  right  ventricle  and  the  right  atrium
ere  observed.  In  both  cases,  the  valve  was  stabilized  close
o  the  tricuspid  annulus  by  overlapping  stents,  using  a  self-
xpandable  Sinus-XL  stent  (OptiMed,  Ettlingen,  Germany)
nd  then  a  balloon-expandable  stent,  before  successful
mplantation  of  a  second  Edwards  SAPIEN  valve  (Fig.  1).
entricular  ectopics  were  noticed  in  two  patients;  these
esolved  in  a  few  days.
aemodynamic  outcomes
he  mean  gradient  decreased  from  9  ±  2.45  mmHg  to
.65  ±  0.7  mmHg  (p  =  0.007).  The  degree  of  valve  regurgi-
ation  improved  in  all  patients  (Table  2).
arly  and  mid-term  outcomes
o  patients  died  during  hospitalization.  Patients  left  the  hos-
ital  about  2  days  after  implantation.  The  mean  follow-up
as  11.6  ±  7.7  months  (range  2—24  months).  The  clinical
onditions  of  all  patients  but  one  were  ameliorated:  eight
atients  were  in  NYHA  class  II,  one  was  in  class  I  and  one
as  in  class  III.  For  the  two  patients  with  protein-losing
nteropathy,  a  signiﬁcant  increase  in  albumin  level  was
oticed  following  the  procedure.  Two  deaths  were  observed
-valve  implantation  (n  =  10).
Valve  size  (mm)  Valve  type
27  Mosaic
33  CE
efect  closure  23  Mitroﬂow
31  CE
onary  artery  hypertension  27  CE
33  CE
ontan  type
33  CE
29  CE
586  
Figure 1. A 16-year-old boy with Ebstein’s anomaly (patient 1).
(A) The ﬁrst 23 mm Edwards SAPIEN valve embolized in the right
ventricle was stabilized by self-expandable stents and Cheatham-
Platinum stents (NuMED, Inc., Hopkinton, NY, USA). Note the second
Edwards SAPIEN valve within the sheath. (B) Final control angiogra-
p
a
c
u
u
(
L
I
t
t
e
c
d
l
i
p
w
m
t
a
i
l
h
p
v
V
a
w
p
t
i
a
1
d
(
a
a
o
o
N
t
f
a
a
D
V
t
c
m
i
p
a
o
s
p
7
f
S
V
r
f
A
Fhy: no tricuspid regurgitation.
fter  implantation:  one  at  10  months  due  to  a  non-cardiac
ause;  and  another  at  5  months  because  of  heart  failure
nrelated  to  tricuspid  valve  dysfunction.  At  latest  follow-
p,  the  mean  gradient  remained  stable  at  4.1  ±  0.7  mmHg
range  3—5.7  mmHg)  (Fig.  2).
iterature review of tricuspid VIV implantationncluding  our  10  patients,  there  were  71  reported  cases  of
ricuspid  VIV  implantation  for  a  failing  bioprosthetic  valve  in
he  literature.  The  initial  pathology  included  rheumatic  dis-
ase  (n  =  13),  Ebstein’s  anomaly  (n  =  12),  endocarditis  (n  =  8),
b
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ardiomyopathy  (n  =  7),  Fontan  tube  failure  (n  =  7),  tricuspid
ysplasia  (n  =  4),  tricuspid  regurgitation  following  ventricu-
ar  septal  defect  closure  (n  =  5)  and  miscellaneous  lesions,
ncluding  atrioventricular  septal  defect  repair  and  carcinoid
athology.
Patient  data  at  implantation  are  listed  in  Table  3.  There
ere  41  women  and  29  men  (the  sex  of  one  patient  was  not
entioned),  and  18  patients  were  aged  ≤  18  years  at  implan-
ation.  To  delineate  the  valvular  stenosis,  balloon  sizing
nd/or  predilatation  was  employed  in  45  patients.  Prestent-
ng  was  performed  in  only  11  patients:  ﬁve  had  a  mixed
esion,  four  had  a  predominant  tricuspid  stenosis  and  two
ad  a  predominant  tricuspid  regurgitation.  Seven  of  these  11
atients  had  subsequent  implantation  of  the  Edwards  SAPIEN
alve  and  four  had  implantation  of  the  22  mm  Melody  valve.
alve  deployment  was  always  realized  under  ﬂuoroscopy,
nd  additive  transoesophageal  echocardiographic  guidance
as  used  in  45  patients.  Postimplantation  dilatation  was
erformed  in  12  patients  (after  Melody  valve  implanta-
ion  in  11  patients  and  Edwards  SAPIEN  valve  implantation
n  one  patient).  Usually,  the  valve  performance  was  good
fter  implantation:  the  maximal  gradient  decreased  from
7.9  ±  4.9  to  7.6  ±  2.4  mmHg  (p  =  0.005)  and  the  mean  gra-
ient  decreased  from  11.0  ±  4.0  mmHg  to  3.8  ±  2.0  mmHg
p  =  0.001).  Regurgitation  was  no  more  than  trivial-to-mild
fter  implantation  in  all  but  one  patient,  who  had  moder-
te  regurgitation  (Table  4).  The  clinical  condition  of  most
f  the  patients  was  ameliorated,  with  a  reduction  in  signs
f  right  heart  failure,  and  all  but  three  patients  were  in
YHA  class  I—II.  The  major  complications  were  emboliza-
ion  (n  =  4),  death  (n  =  2)  and  endocarditis  (n  =  1).  The  mean
ollow-up  was  6.7  ±  6.5  months  (range  0.25—30  months),
nd  at  latest  follow-up  the  mean  gradient  remained  stable
t  4.4  ±  1.3  mmHg.
iscussion
IV  procedures  are  being  performed  increasingly  as  a
reatment  for  degenerated  bioprostheses.  In  fact,  when  a
ircumferential  valvular  ring  is  present,  it  may  provide  the
inimal  landing  zone  to  anchor  a  valved  stent,  thus  allow-
ng  transcatheter  VIV  implantation  [1,4].  Although  this  latter
rocedure  has  been  performed  preferentially  in  degener-
ted  aortic  bioprostheses,  there  have  been  many  reports
f  transcatheter  VIV  implantation  in  the  tricuspid  position
ince  the  ﬁrst  implantation  in  2010.  A  series  of  10  patients  is
resented  here  and  a  review  of  literature  identiﬁed  a  total  of
1  implantations.  The  valved  stent  was  implanted  success-
ully  in  all  patients  using  either  a  Melody  valve  or  an  Edwards
APIEN  valve.  Our  report  demonstrates  that  transcatheter
IV  implantation  can  be  achieved  and  has  now  become  a
eal  alternative  to  surgery  for  bioprosthetic  tricuspid  valve
ailure.
ccess route
or  tricuspid  VIV  implantation,  different  approaches  have
een  proposed  (e.g.  from  the  superior  vena  cava,  the  right
ugular  vein  and  the  standard  femoral  vein,  as  well  as
he  surgical  open  transatrial  or  transapical  approaches)
5—12].  The  last  two  approaches  would  probably  not  be
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Table  2  Pre-  and  postimplantation  haemodynamic  data:  unpublished  cases  of  tricuspid  valve-in-valve  implantation
(n  =  10).
Patient  Type  of
lesion
Valved
stent
Mean gradient
(mmHg)
Regurgitation  Balloon
sizing
Prestenting  Pacing  Complications
Pre Post Pre  Post
1  TS  + TR  Edwards  23  10  4  Moderate  Trivial  Yes  No  Yes  Migration
2  TS  + TR  Edwards  26  6  4  Severe  Trivial  Yes  One  MaxTM LD
stenta
Yes
3  TS  + TR Melody  22 8  5  Severe  None  Yes  Two  covered
CPTM stentsb;
one  Max  LD
stent  +  one  CP
stent
Yes
4  TS  Melody  22  9  4  Mild  None  Yes  No  No
5  TS  Edwards  29  10  4  No  One  Max  LD
stent;  one  CP
stent
No Migration;
ectopics
6  TS  Melody  22  14  3  Mild  Trivial  Yes  No  No
7  TR  Melody  22  2.9  Severe  Trivial  Yes  One  covered
CP  stent;  one
MegaTM LD
stenta
No
8  TS  Melody  22  10  3.6  Mild  None  Yes  One  Max  LD
stent;  one
covered  CP
stent
No Ectopics
9  TS  + TR  Melody  22  8  3  Severe  None  Yes  One  covered
CP  stent;  one
Mega  LD  stent
No
10  TS  + TR  Melody  22  6  3  Severe  Trivial  Yes  No  No
CP: Cheatham-Platinum; TR: tricuspid regurgitation; TS: tricuspid stenosis.
a ev3 Endovascular, Inc., Plymouth, MN, USA.
b NuMED, Inc., Hopkinton, NY, USA.
p
l
t
e
i
t
d
s
r
f
i
s
b
s
t
I
a
awell  tolerated  in  some  high-risk  patients  and  would  increase
postprocedural  morbidity.  Because  the  tricuspid  valve  is
often  directed  towards  the  superior  vena  cava,  many  authors
have  recommended  the  jugular  approach,  to  obtain  a bet-
ter  angle  and  a  more  stable  aligned  position  during  valve
deployment  [1,4,13—26].  However,  this  is  more  theoretical
than  real,  especially  with  the  use  of  an  extra-stiff  guidewire
or  the  steerable  balloon  catheter  of  the  Edwards  SAPIEN
valve  [3,27].  In  fact,  many  reports  have  shown  the  success-
ful  employment  of  the  more  classical  femoral  venous  route,
which  offers  the  advantage  of  convenience  and  familiarity
[3,16,20,22,24,27—36].
Choice of valved stent and deployment
Exact  knowledge  of  the  true  internal  diameter  of  the
failed  bioprosthesis  (minimal  diameter  and  its  delineation)
is  the  key  point  for  VIV  implantation;  this  can  be  measured
by  transoesophageal  echocardiography  and/or  computed
tomography  [2,3,7,12,15,16,27,28,32].  In  fact,  the  man-
ufacturer’s  information  about  the  characteristics  of  the
valve  itself  is  most  important  when  making  the  deci-
sion,  with  knowledge  of  internal  (inner  stent)  diameter,
d
t
i
prosthesis  height,  type  of  base  ring  and  position  and  angu-
ation  of  stent  posts  [2,12,37]. However,  calciﬁed,  bulky  or
orn  leaﬂets  and  pannus  may  also  reduce  the  internal  diam-
ter.  Balloon  sizing  with  a  low-pressure  balloon  catheter
s  another  technique  for  delineating  the  true  inner  diame-
er  [4,16,18,21,22,24,31,32,36]. Sometimes,  a true  balloon
ilatation  may  also  be  employed,  especially  if  the  valve  is
everely  stenosed  [3,7,11,18,19,22,25—31,34], but  this  is
arely  necessary  due  to  antegrade  crossing  as  performed
or  tricuspid  VIV  implantation  [2]. Furthermore,  dilatation
s  not  always  recommended  because  of  concerns  about  pos-
ible  valve  disintegration  and  damage  following  inﬂation,
ut  this  risk  seems  low  [2,37].
In  fact,  the  external  diameter  of  the  valved  stent
hould  match  and  even  exceed  the  true  internal  diame-
er  of  the  failed  bioprosthesis,  to  avoid  dislocation  [2,37].
deally,  the  radio  markers  at  the  basal  ring  (if  avail-
ble)  should  be  ‘straight’  aligned  and  perpendicular  to  the
xis  of  the  delivery  sheath  on  ﬂuoroscopy  during  valve
eployment.  Additional  imaging  using  (three-dimensional)
ransoesophageal  [3,6—10,12,14—21,24—27,29,32—34]  or
ntracardiac  echocardiography  has  also  been  used  for  appro-
riate  deployment.
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Figure 2. Transthoracic echocardiography 15 months after
implantation (patient 1) demonstrates adequate position and func-
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Table  3  Patient  data:  literature  review  of  tricuspid
valve-in-valve  implantation  (n  =  71).
Age  (years)  42.5  ±  23  (8—84)
Weight  (kg) 62.6  ±  22.2  (22—110)
Previous  tricuspid
surgeries  (n)
2.2 ±  1.1  (1—5)
Diameter  of  the
failing
bioprosthesis
(mm)
27.6  ±  3.7  (14—33)
Delay  (years)  10.3  ±  6.9  (1.5—32)
NYHA  functional
class
Class  III  23
Class  IV  14
Class  II  7
Class  I 1
Not  mentioned 26
Cause  of  VIV
implantation
TS  29
TR  9
TS  + TR 32
Not  mentioned 1
Data are mean ± standard deviation (range) or number. NYHA:
New York Heart Association; TR: tricuspid regurgitation; TS:
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tion across the tricuspid valve by colour (A) and pulsed-wave (B)
oppler.
There  are  two  valves  available  for  VIV  implantation  in
he  tricuspid  position  (the  Melody  valve  and  the  Edwards
APIEN  valve);  superiority  of  one  over  the  other  has  not  been
stablished.  The  advantage  of  the  latter  is  its  availability  in
arger  sizes,  increasing  the  number  of  patients  who  can  be
reated.  However,  this  may  be  limited  by  the  small  length
f  the  stent  and  the  possible  risk  of  embolization.
restenting
t  has  been  reported  that  prestenting  is  not  mandatory
or  VIV  implantation  in  the  tricuspid  position.  However,  as
bserved  in  two  of  our  patients,  it  is  advisable  to  obviate
alve  dislocation  [33].  In  fact,  this  is  related  to  different
actors,  including  the  bioprosthesis  type  and  its  anatomical
haracteristics  [2].  For  the  interventionists,  the  real  land-
ng  zone  and  target  for  VIV  implantation  is  the  sewing  ring
nd  stent  posts.  It  seems  that  for  patients  with  just  a  ring,
restenting  is  wise,  as  it  provides  a  longer  ‘landing  zone’;
his  is  also  true  for  some  of  the  short  Edwards  SAPIEN  valves
2,18,19,24,33].  Prestenting  has  also  been  employed  in  a
atient  with  predominant  tricuspid  regurgitation,  using  the
dwards  SAPIEN  valve  for  a  similar  reason  [27,33]. Other
han  under  the  above  conditions,  prestenting  is  not  neces-
ary  for  the  vast  majority  of  patients.
m
e
d
ttricuspid stenosis; VIV: valve-in-valve.
Of  interest  is  the  technique  of  annulus  reduction  as  per-
ormed  in  our  ‘‘patient  3’’;  no  Edwards  SAPIEN  valve  was
vailable  at  this  time.  By  implanting  four  stents,  the  annulus
eduction  was  effective,  allowing  successful  implantation  of
 22  mm  Melody  valve.  The  use  of  an  Edwards  SAPIEN  valve
ight  have  been  an  alternative  strategy.
apid pacing
apid  pacing  with  a  lead  placed  in  the  left  ventricle
rarely  in  the  coronary  sinus)  has  also  been  proposed
o  obtain  a  stable  position  during  valve  deployment
1,3,6,7,9—12,15,19,20,25,27,28].  Sometimes,  the  heart  is
brillated  with  ‘spinal’  needles  during  implantation,  using  a
ransatrial  approach  [6,9]. However,  with  the  low  gradient
cross  the  tricuspid  valve,  this  may  be  not  necessary  [2,26].
acing  is,  in  fact,  mainly  dependent  on  local  preferences
nd  can  be  recommended  if  cardiac  motions  are  problem-
tic,  especially  in  case  of  signiﬁcant  tricuspid  regurgitation
2,27].
omplications
mbolization  of  the  valved  stent  in  the  right-sided  cardiac
hambers  or  pulmonary  artery  is  the  major  complication
ssociated  with  this  technique  [38],  and  may  be  related
o  the  lack  of  coaxiality  during  inﬂation  and/or  subopti-
al  deployment  position  and/or  valve  mismatch.  Cocchieri
t  al.  reported  distal  embolization  in  the  pulmonary  artery
ue  to  undersizing  after  using  a  transatrial  approach  [7].  In
his  setting,  different  options  could  be  considered:  stenting
Tricuspid  VIV  implantation  
Table  4  Procedural  data:  literature  review  of  tricuspid
valve-in-valve  implantation  (n  =  71).
Approach
Femoral  36
Jugular  19
Transatrial  9
Not  mentioned  1
Balloon  sizing  16
Predilatation  22
Prestenting  11
Valved  stent
22  mm  Melody  valve 40
26  mm  Edwards  SAPIEN
valve
20
29  mm  Edwards  SAPIEN
valve
6
23  mm  Edwards  SAPIEN
valve
3
18  mm  Melody  valve 1
28  mm  Braile  valvea 1
Postimplantation
dilatation
12
Peak  gradient
preimplantation
(mmHg)
17.9  ±  4.9  (7—27)
Mean  gradient
preimplantation
(mmHg)
11.0  ±  4.0  (3—20)
Peak  gradient
postimplantation
(mmHg)
7.6  ±  2.4  (3—12)
Mean  gradient
postimplantation
(mmHg)
3.8  ±  2.0  (0—9)
Preimplantation  TR
Mild-to-trivial
regurgitation
Moderate-to-severe
regurgitation
17
Not  mentioned  41
Postimplantation  TR  13
Trivial  regurgitation  26
None  18
Mild  regurgitation  10
Moderate  regurgitation  1
Not  mentioned 16
Data are number or mean ± standard deviation (range). TR:
tricuspid regurgitation.
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the  dislocated  valve  in  the  pulmonary  artery  branch;  extrac-
tion  into  a  large  sheath  with  a  biopsy  forceps  [7];  or  surgical
extraction  with  tricuspid  valve  replacement.  True  emboliza-
tion  in  the  right  ventricle  or  atrium  —  as  reported  here  in  two
patients  with  an  Edwards  SAPIEN  valve  —  has  not  yet  been
reported.  Some  have  proposed  positioning  the  short  Edwards
SAPIEN  valve  more  atrially  within  the  tricuspid  annulus  to
reduce  this  risk  [15].  In  fact,  anchoring  the  embolized  valve
close  to  the  tricuspid  annulus  by  overlapping  stents  was  the
v
b
t589
trategy  employed  in  these  patients.  This  was  made  pos-
ible  by  implantation  of  a  self-expandable  stent  and  then
tiffer  stents,  allowing  a  second  successful  VIV  implanta-
ion.  We  clearly  recommend  this  approach  for  embolization
n  the  right  ventricle  if  no  wall  protrusion  by  the  stent  can
e  anticipated.  A  similar  overlapping  stents  approach  has
lso  been  reported  in  a  patient  with  slight  migration  of  an
dwards  SAPIEN  valve  in  the  ventricular  direction  [20].
Endocarditis  is  another  matter  for  concern  and  a  clas-
ic  risk  with  bioprostheses.  To  our  best  knowledge,  only  one
ase  has  been  reported  after  a  Melody  valve  implantation,
n  a  9-year-old  patient  following  four  tricuspid  replace-
ents  for  Ebstein’s  anomaly  [22]. Such  limited  risk  has  to
e  interpreted  with  great  caution  because  of  the  short-term
ollow-up.  In  addition,  we  clearly  insist  on  the  necessity  of
ntibiotic  prophylaxis  after  the  procedure.
Valvular  failure  is  another  issue  usually  observed  over
ime  with  all  bioprostheses.  Progressive  early  regurgitation
as  noticed  in  a  patient  who  received  the  22  mm  Melody
alve  implanted  over  a  24-mm  balloon  [22], but  this  may
ave  been  the  consequence  of  overdilatation.  One  early
alve  thrombosis  has  also  been  reported  (18  days  after  a
elody  valve  implantation),  but  this  was,  in  fact,  related  to
eparin-induced  thrombocytopoenia  [16].
Other  drawbacks  have  included  third-degree  heart
lock  requiring  pacemaker  implantation  [22],  minor  neck
aematoma  [21], phlebitis,  femoral  artery  pseudoaneurysm
16]  and  pleural  effusion  [15].  Pulmonary  artery  bleeding
ue  to  perforation  by  the  distal  wire  tip  has  also  been
eported;  this  was  corrected  successfully  by  coil  implanta-
ion  [32].  Some  of  these  vascular  complications  are  clearly
elated  to  the  use  of  a  large  delivery  sheath  and  (probably)
o  patient  comorbidities  [16].
Death  has  been  reported  twice  in  the  literature  after
mplantation  of  the  Melody  and  Edwards  SAPIEN  valves
6,22]. In  fact,  although  transcatheter  VIV  implantation
eems  less  aggressive  than  surgery  for  these  patients  in  poor
onditions,  there  is  a  persistent  minimal  risk  of  morbidity
nd/or  mortality  following  such  a  procedure.
Finally,  stent  fracture  is  another  matter  for  concern,  and
as  been  reported  mainly  with  the  Melody  valve  implanted
n  the  right  ventricular  outﬂow  tract.  By  comparison,  VIV
mplantation  in  the  tricuspid  position  seems  less  problematic
ecause  the  valved  stent  is  placed  within  a  bioprosthetic
alve  with  less  mechanical  restraint.
mplantation in native valve
mplantation  within  a  native  tricuspid  annulus  is  clearly  a
ore  challenging  procedure.  This  issue  has  already  been
ddressed  in  an  animal  model  by  Iino  et  al.  [38]  and  Boud-
emline  et  al.  [39]. Both  groups  developed  an  original
elf-expandable  stent  in  which  a  bioprosthesis  was  mounted,
llowing  reduction  of  the  tricuspid  annulus.  Although  this
oncept  was  effective  and  promising  in  animals,  creating
 potential  landing  zone  for  further  deployment  of  the
alved  stent,  unfortunately  it  has  not  yet  been  developed
n  humans.There  is  only  one  case  report  in  the  literature  of  tricuspid
alve  implantation  in  a native  valve  repaired  three  times,
ut  without  previous  surgical  ring  or  bioprosthesis  [32].  In
he  same  way,  but  less  challenging,  tricuspid  valve-in-ring
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VIR)  has  also  been  reported  within  a  Carpentier-Edwards
ing  in  one  patient  [10]  and  a  Physio  ring  combined  with  a
itral  homograft  in  two  other  patients,  thus  enabling  VIV
nd  VIR  procedures  [19,40].  Here,  the  stiffness  of  the  ring
llowed  appropriate  anchoring  of  the  Edwards  SAPIEN  valve
4].  These  authors  proposed  placing  the  valved  stent  more
istally  in  the  ring,  with  one  third  in  the  atrium  and  two
hirds  in  the  ventricle,  for  two  reasons:  ﬁrst,  to  reshape  the
symmetric  form  of  the  ring  into  a  circular  form;  and  second,
o  reduce  the  risk  of  paravalvular  leak  by  the  short  basal  cuff
f  the  Edwards  SAPIEN  valve  [10].  All  these  strategies  will
robably  modify  the  current  standard  of  care  for  atrioven-
ricular  valve  replacement,  by  ﬁrst  placing  a  bioprosthesis
r  performing  an  annuloplasty  ring.  Then,  when  the  valve
egenerates,  a  VIV  or  VIR  implantation  will  be  performed,
hus  avoiding  another  surgical  repair.
imitations
here  are  some  limitations  to  the  present  review.  Data  were
ollected  from  a  ‘PubMed’  search  and  we  may  have  missed  a
ew  cases,  including  failed  procedures,  which  are  often  not
ublished.  Most  of  the  implantations  were  performed  ‘off
abel’,  mainly  on  high-risk  patients,  which  may  have  modi-
ed  the  rate  of  complications.  In  addition,  some  results  and
rawbacks  may  also  have  been  inﬂuenced  by  the  learning
urve  associated  with  this  early  experience.  Furthermore,
e  should  acknowledge  that  small  numbers  of  cases  are
nsufﬁcient  to  enable  ﬁnal  recommendations  to  be  made.
ollection  of  more  data  and  longer  follow-up  by  creation  of
 registry  are  needed  in  the  future  to  establish  the  best  strat-
gy  for  patients  with  a  failing  tricuspid  bioprosthesis.  Finally,
ong-term  deterioration  of  these  valved  stents  should  also
e  anticipated,  as  classically  observed  with  all  bioprosthetic
alves.
onclusion
ricuspid  VIV  implantation  using  the  Melody  valve  or  the
dwards  SAPIEN  valve  is  a  relatively  new  technique  and  a
eproducible  therapeutic  option;  it  is  an  interesting  alterna-
ive  to  surgery  for  selected  high-risk  patients  with  a  failing
ricuspid  bioprosthesis,  which  provides  a  less  aggressive
pproach.  However,  further  experience  is  required  to  help
n  the  standardization  and  dissemination  of  this  appealing
rocedure.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
eferences
[1] Gewillig M, Dubois C. Percutaneous re-revalvulation of the tri-
cuspid valve. Catheter Cardiovasc Interv 2011;77:692—5.
[2] Gurvitch R, Cheung A, Ye J, et al. Transcatheter valve-in-valve
implantation for failed surgical bioprosthetic valves. J Am Coll
Cardiol 2011;58:2196—209.
[F.  Godart  et  al.
[3] Hanna BM, Rodes-Cabau J, Dahdah N. Percutaneous transcat-
heter valve-in-valve implantation with the balloon-expandable
valve for the treatment of a dysfunctional tricuspid bio-
prosthetic valve: a pediatric case report. J Invasive Cardiol
2013;25:310—2.
[4] Petit CJ, Justino H, Ing FF. Melody valve implantation in the
pulmonary and tricuspid position. Catheter Cardiovasc Interv
2013;82:E944—6.
[5] Beckerman Z, Cohen O, Agmon Y, Bolotin G. Valve-in-valve in
the tricuspid position for a stenosed bioprosthesis. Heart Surg
Forum 2013;16:E96—8.
[6] Cheung A, Soon JL, Webb JG, Ye J. Transatrial transcathe-
ter tricuspid valve-in-valve technique. J Card Surg 2012;27:
196—8.
[7] Cocchieri R, Wiegerinck EM, de Groot JR, et al. Troubleshooting
in transatrial tricuspid valve-in-valve implantation. Ann Thorac
Surg 2012;94:1349—52.
[8] Gaia DF, Palma JH, de Souza JA, Buffolo E. Tricuspid transcat-
heter valve-in-valve: an alternative for high-risk patients. Eur
J Cardiothorac Surg 2012;41:696—8.
[9] Hon JK, Cheung A, Ye J, et al. Transatrial transcatheter
tricuspid valve-in-valve implantation of balloon-expandable
bioprosthesis. Ann Thorac Surg 2010;90:1696—7.
10] Mazzitelli D, Bleiziffer S, Noebauer C, et al. Transatrial ante-
grade approach for double mitral and tricuspid ‘‘valve-in-ring’’
implantation. Ann Thorac Surg 2013;95:e25—7.
11] Nielsen HH, Egeblad H, Klaaborg KE, Hjortdal VE, Thuesen
L. Transatrial stent-valve implantation in a stenotic tricuspid
valve bioprosthesis. Ann Thorac Surg 2011;91:e74—6.
12] Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve
implantation for failed bioprosthetic heart valves. Circulation
2010;121:1848—57.
13] Bhamidipati CM, Scott Lim D, Ragosta M, Ailawadi G. Per-
cutaneous transjugular implantation of MELODY(R) valve into
tricuspid bioprosthesis. J Card Surg 2013;28:391—3.
14] Cerillo AG, Berti S, Glauber M. Transjugular tricuspid valve-in-
valve implantation: a safe and effective approach. Ann Thorac
Surg 2011;92:777—8.
15] Cerillo AG, Chiaramonti F, Murzi M, et al. Transcatheter
valve-in-valve implantation for failed mitral and tricuspid bio-
prosthesis. Catheter Cardiovasc Interv 2011;78:987—95.
16] Cullen MW, Cabalka AK, Alli OO, et al. Transvenous, antegrade
Melody valve-in-valve implantation for bioprosthetic mitral and
tricuspid valve dysfunction: a case series in children and adults.
JACC Cardiovasc Interv 2013;6:598—605.
17] Daneault B, Williams MR, Leon MB, Paradis JM, Kodali SK. Trans-
catheter tricuspid valve-in-valve replacement resulting in 4
different prosthetic heart valves in a single patient. J Am Coll
Cardiol 2013;61:e3.
18] De Meester P, Budts W,  Gewillig M. Transvenous valve-in-
valve replacement preserving the function of a transvalvu-
lar deﬁbrillator lead. Catheter Cardiovasc Interv 2014,
http://dx.doi.org/10.1002/ccd.25451.
19] Lilly SM, Rome J, Anwaruddin S, et al. How should I treat pros-
thetic tricuspid stenosis in an extreme surgical risk patient?
EuroIntervention 2013;9:407—9.
20] Mick SL, Kapadia S, Tuzcu M, Svensson LG. Transcathe-
ter valve-in-valve tricuspid valve replacement via internal
jugular and femoral approaches. J Thorac Cardiovasc Surg
2014;147:e64—5.
21] Roberts P, Spina R, Vallely M, Wilson M, Bailey B, Celermajer
DS. Percutaneous tricuspid valve replacement for a stenosed
bioprosthesis. Circ Cardiovasc Interv 2010;3:e14—5.
22] Roberts PA, Boudjemline Y, Cheatham JP, et al. Percutaneous
tricuspid valve replacement in congenital and acquired heart
disease. J Am Coll Cardiol 2011;58:117—22.
23] Salizzoni S, La Torre M, Barbero C, et al. Transjugular tricuspid
valve-in-valve implantation. Heart Lung Circ 2013;22:1036—9.
[[
[
[
[
[
[
[Tricuspid  VIV  implantation  
[24] Tzifa A, Momenah T, Al Sahari A, Al Khalaf K, Papagiannis J,
Qureshi SA. Transcatheter valve-in-valve implantation in the
tricuspid position. Euro Intervention 2014 [pii: 20130315-01].
[25] Van Garsse LA, Ter Bekke RM, van Ommen VG. Percutaneous
transcatheter valve-in-valve implantation in stenosed tricuspid
valve bioprosthesis. Circulation 2011;123:e219—21.
[26] Weich H, Janson J, van Wyk J, Herbst P, le Roux P, Doubell A.
Transjugular tricuspid valve-in-valve replacement. Circulation
2011;124:e157—60.
[27] Hoendermis ES, Douglas YL, van den Heuvel AF, Percutaneous
Edwards SAPIEN. valve implantation in the tricuspid posi-
tion: case report and review of literature. EuroIntervention
2012;8:628—33.
[28] Calvert PA, Himbert D, Brochet E, et al. Transfemoral
implantation of an Edwards SAPIEN valve in a tricuspid bio-
prosthesis without ﬂuoroscopic landmarks. EuroIntervention
2012;7:1336—9.
[29] Eicken A, Fratz S, Hager A, Vogt M, Balling G, Hess J. Tran-
scutaneous Melody valve implantation in ‘‘tricuspid position’’
after a Fontan Bjork (RA-RV homograft) operation results in
biventricular circulation. Int J Cardiol 2010;142:e45—7.
[30] Greif M, Schramm R, Steinbeck G, Hagl C, Schmitz C, Kupatt
C. Transfemoral access for valve-in-valve implantation of an
Edwards Sapien XT valve in a stenotic tricuspid biopros-
thesis under ﬂuoroscopic guidance. Can J Cardiol 2013;29:
1014e3—4.
[31] Jux C, Akintuerk H, Schranz D. Two Melodies in concert:
transcatheter double-valve replacement. Catheter Cardiovasc
Interv 2012;80:997—1001.
[591
32] Kefer J, Sluysmans T, Vanoverschelde JL. Transcatheter Sapien
valve implantation in a native tricuspid valve after failed sur-
gical repair. Catheter Cardiovasc Interv 2014;83:841—5.
33] Kenny D, Hijazi ZM, Walsh KP. Transcatheter tricuspid valve
replacement with the Edwards SAPIEN valve. Catheter Cardio-
vasc Interv 2011;78:267—70.
34] Ribichini F, Pesarini G, Feola M, et al. Transcatheter tricus-
pid valve implantation by femoral approach in trivalvular heart
disease. Am J Cardiol 2013;112:1051—3.
35] Riede FT, Dahnert I. Implantation of a Melody valve in tricuspid
position. Catheter Cardiovasc Interv 2012;80:474—6.
36] Straver B, Wagenaar LJ, Blom NA, et al. Percutaneous tricuspid
valve implantation in a Fontan patient with congestive heart
failure and protein-losing enteropathy. Circ Cardiovasc Interv
2011;4:112—3.
37] Latib A, Ielasi A, Montorfano M, et al. Transcatheter valve-in-
valve implantation with the Edwards SAPIEN in patients with
bioprosthetic heart valve failure: the Milan experience. EuroIn-
tervention 2012;7:1275—84.
38] Iino K, Lozonschi L, Metzner A, et al. Tricuspid valved
stent implantation: novel stent with a self-expandable super-
absorbent polymer. Eur J Cardiothorac Surg 2011;40:503—7.
39] Boudjemline Y, Agnoletti G, Bonnet D, et al. Steps toward the
percutaneous replacement of atrioventricular valves an exper-
imental study. J Am Coll Cardiol 2005;46:360—5.40] Fassa AA, Himbert D, Brochet E, Labbe JP, Vahanian
A. Transfemoral valve-in-ring implantation for a failing
mitral homograft in the tricuspid position. EuroIntervention
2014;10:269.
